Cimetidine does not alter the clearance or plasma binding of tenidap in healthy male volunteers.
1. An open-label, placebo-controlled study was conducted to examine the effect of cimetidine on the steady-state pharmacokinetics of tenidap. 2. Twenty-four healthy volunteers received tenidap sodium (120 mg) each morning throughout the study. On day 14 plasma levels of tenidap had reached steady state; half of the subjects were treated concomitantly with cimetidine 800 mg at night, while the other half received placebo. Allocation of cimetidine or placebo was randomised. Plasma profiles of tenidap were measured on days 14 and 16. 3. The addition of cimetidine did not significantly affect the Cmax, tmax, or lambda z of tenidap. The AUC(0,24h) increased by 4% between days 14 and 16 in the cimetidine treatment group, compared with a decrease of 2% in the placebo group. This small difference is statistically significant (P = 0.047), but it is not considered to be clinically relevant. 4. It is concluded that concomitant administration of cimetidine does not significantly affect the pharmacokinetics of tenidap at steady state.
Wilner
K D
KD
Central Research Division, Pfizer Inc., Groton, CT 06430, USA.
Gardner
M J
MJ
D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood / Q000493:pharmacokinetics; D002927:Cimetidine / Q000494:pharmacology*; D004311:Double-Blind Method; D004347:Drug Interactions; D006801:Humans; D007211:Indoles / Q000097:blood* / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D000078183:Oxindoles; D011485:Protein Binding / Q000187:drug effects; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007211:Indoles; D000078183:Oxindoles; D002927:Cimetidine; C062866:tenidap